SGLT2 inhibitors

50 all articles · 20 / page

Ask MedXY AI

Latest news

Tag

All articles

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

A multinational real-world study found broadly similar cardiovascular effectiveness across individual GLP-1 receptor agonists and SGLT2 inhibitors in metformin-treated type 2 diabetes, including among patients with established cardiovascula

Section: CardiologyJun 10, 2026

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

A validation study developed SABRE, a model that estimates how much SGLT2 inhibitors can reduce heart failure risk in people with type 2 diabetes, helping clinicians target preventive treatment more precisely.

SGLT2 inhibitors

Latest news

Individual GLP-1 Receptor Agonists and SGLT2 Inhibitors Show Largely Comparable Cardiovascular Protection in Type 2 Diabetes

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

Precision Prescribing of SGLT2 Inhibitors in People With Type 2 Diabetes for Primary Prevention of Heart Failure: Model Development and Validation Study

Precision Prescribing of SGLT2 Inhibitors in Type 2 Diabetes for Primary Prevention of Heart Failure

No Clear Winner: Real-World Evidence Shows GLP-1RAs and SGLT2 Inhibitors Deliver Comparable Cardiovascular Benefits in Type 2 Diabetes

SGLT2 Inhibitors Do Not Increase Amputation Risk in Diabetic Foot Ulcer: Study Reveals Significant Mortality Benefit

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis

Uncoupling Metabolic Benefit from Glycemic Control: Empagliflozin’s Superiority Over Insulin in Beta Cell Preservation

SGLT2 Inhibitors Reduce Gout-Related Medication Burden in Patients with Type 2 Diabetes

SGLT2 Inhibition and Atrial Fibrillation Recurrence Post-Ablation: Insights from the DARE-AF Randomized Clinical Trial

SGLT2 Inhibitors Offer Potent Protection Against Contrast-Induced Kidney Injury During Coronary Intervention

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes

Beyond Glycemic Control: How SGLT2 and DPP-4 Inhibitor Combinations Rescue the Urinary Microbiome in Type 2 Diabetes

Beyond Glycemic Control: Empagliflozin/Linagliptin Combination Restores Urinary Microbiota Homeostasis in Type 2 Diabetes

Precision Medicine Outperforms Standard Albuminuria Thresholds for SGLT2 Inhibitor Selection in Type 2 Diabetes

Dapagliflozin Improves Vascular Stiffness and Cardiorenal Hemodynamics: New Insights from a Randomized Controlled Trial

SGLT2 Inhibitors Edge Out GLP-1 RAs in Kidney Protection: Insights from a Target Trial Emulation

Challenging the Metformin Monopoly: Insights from the SMARTEST Trial on Early-Stage Type 2 Diabetes Management